Suzetrigine as a Novel Non-opioid Analgesic Drug in Pain Management: A Review of Clinical Evidence and Therapeutic Perspectives

The NaV1.8 sodium channel plays a key role in the transmission of pain signals in peripheral sensory neurons. Suzetrigine is a selective NaV1.8 inhibitor developed as a non-opioid analgesic. Its action is limited to sensory neurons, reducing the risk of adverse effects associated with non-selective sodium channel blockers. Phase II and III clinical trials have demonstrated the high efficacy of suzetrigine in managing postoperative pain, along with good tolerability. Adverse events, such as dizziness or drowsiness, were rare and generally mild to moderate in intensity. The drug did not cause respiratory depression or addiction, which distinguishes it from opioids. Ongoing pharmacokinetic studies and long-term observations aim to further define the drug's safety profile and its potential use in patients with comorbid conditions. Suzetrigine may offer an effective and safe alternative to opioids in pain treatment.